Recent advances in immunopeptidomic-based tumor neoantigen discovery DOI
Wei Meng, Robert D. Schreiber, Cheryl F. Lichti

et al.

Advances in immunology, Journal Year: 2023, Volume and Issue: unknown, P. 1 - 36

Published: Jan. 1, 2023

Language: Английский

IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma DOI Creative Commons
Maria Wahle, Marvin Thielert, Maximilian Zwiebel

et al.

Molecular & Cellular Proteomics, Journal Year: 2023, Volume and Issue: 23(1), P. 100689 - 100689

Published: Dec. 1, 2023

Distinction of non-self from self is the major task immune system. Immunopeptidomics studies peptide repertoire presented by human leukocyte antigen (HLA) protein, usually on tissues. However, HLA peptides are also bound to plasma soluble (sHLA), but little known about their origin and potential for biomarker discovery in this readily available biofluid. Currently, immunopeptidomics hampered complex workflows limited sensitivity, typically requiring several mL plasma. Here, we take advantage recent improvements throughput sensitivity mass spectrometry (MS)-based proteomics develop a highly sensitive, automated, economical workflow analysis, termed Biotinylated Antibodies Streptavidin (IMBAS). IMBAS-MS quantifies more than 5000 class I only 200 μl plasma, just 30 min. Our technology revealed that immunopeptidome healthy donors remarkably stable throughout year strongly correlated between individuals with overlapping types. Immunopeptides originating diverse tissues, including brain, proportionately represented. We conclude sHLAs promising avenue immunology potentially precision oncology.

Language: Английский

Citations

9

Immunopeptidomics in the Era of Single-Cell Proteomics DOI Creative Commons
Rupert L. Mayer, Karl Mechtler

Biology, Journal Year: 2023, Volume and Issue: 12(12), P. 1514 - 1514

Published: Dec. 12, 2023

Immunopeptidomics, as the analysis of antigen peptides being presented to immune system via major histocompatibility complexes (MHC), is seen an imperative tool for identifying epitopes vaccine development treat cancer and viral bacterial infections well parasites. The field has made tremendous strides over last 25 years but currently still faces challenges in sensitivity throughput widespread applications personalized medicine large studies. Cutting-edge technological advancements sample preparation, liquid chromatography mass spectrometry, data analysis, however, are transforming field. This perspective showcases how advent single-cell proteomics accelerated this transformation immunopeptidomics recent will pave way even more sensitive higher-throughput analyses.

Language: Английский

Citations

7

Exploring the dynamic landscape of immunopeptidomics: Unravelling posttranslational modifications and navigating bioinformatics terrain DOI Creative Commons
Daniel Flender, Frédérique Vilenne, Charlotte Adams

et al.

Mass Spectrometry Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 16, 2024

Abstract Immunopeptidomics is becoming an increasingly important field of study. The capability to identify immunopeptides with pivotal roles in the human immune system essential shift current curative medicine towards personalized medicine. Throughout years, has matured, giving insight into pitfalls. Nowadays, it commonly accepted that generalizing shotgun proteomics workflows malpractice because immunopeptidomics faces numerous challenges. While many these difficulties have been addressed, road ideal workflow remains complicated. Although presence Posttranslational modifications (PTMs) immunopeptidome demonstrated, their identification highly challenging despite significance for immunotherapies. large number unpredictable plays a role functionality and This review provides comprehensive overview advancements immunopeptidomics. We delve challenges associated identifying PTMs within immunopeptidome, aiming address state field.

Language: Английский

Citations

2

Discovery of T Cell Epitopes for Cancer Immunotherapy DOI
Gabriela Zuleger, Angela M. Krackhardt, Michael Hiltensperger

et al.

Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

T cell antigens are important targets for cancer immunotherapy in the form of vaccines or adoptive therapy. These a result tumorigenesis and can be either tumor-associated tumor-specific, depending on their presentation tumor normal cells. Genetic aberrations that formation tumor-specific neoantigens particular great interest due to potential, good tolerability, lack self-tolerance. Discovery epitopes is an active area research, new experimental computational pipelines constantly developed. In this chapter, we give overview some antigen- receptor (TCR)-centered discovery methods identification epitopes. Moreover, talk about characterization identified regard features immunotherapy.

Language: Английский

Citations

0

Lab-on-a-chip for In Vitro Diagnosis: Manipulating the Power of Nanoparticles DOI
Zouhair Ait‐Touchente, Sumera Khizar,

Nadia Zine

et al.

Royal Society of Chemistry eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 244 - 271

Published: Aug. 14, 2024

Lab-on-a-chip (LOC) technology, in conjunction with nanoparticles, offers a promising approach for vitro diagnosis. The pivotal role of nanoparticles LOC-based diagnostics is elaborated this chapter, covering their properties, functionalization techniques, and key applications. fundamentals LOC including microfluidics on-chip laboratory function integration, are discussed, emphasizing the advantages systems diagnostic applications such as miniaturization increased efficiency. Functionalized enable specific biomarker targeting enhance detection sensitivity, leading to more precise reliable diagnoses. significance efficient sample preparation handling successful diagnosis underscored, alongside use purification, concentration, manipulation using devices. chapter further explores assay development detection, highlighting nanoparticles’ utility labels or probes. Their employment amplification strategies multiplexing enables heightened sensitivity simultaneous multiple analytes. application technology point-of-care (POC) examined, its terms portability, rapid testing, improved healthcare accessibility. Integrating nanoparticle-based assays into POC settings facilitates faster accurate diagnoses at point need. concludes by discussing challenges, future perspectives, potential advancements field.

Language: Английский

Citations

0

MAETi: Mild acid elution in a tip enables quantitative immunopeptidome profiling from 25,000 cells DOI Creative Commons
Julian Beyrle, Ute Distler, David Gomez‐Zepeda

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 21, 2024

3 Abstract The identification of MHC class I presented ligands by mass spectrometry (MS)-based immunopeptidomics is an essential tool to characterize antigen processing pathways and define targets for tumor immunotherapies. However, existing sample preparation workflows typically require large inputs, limiting the applicability in high throughput drug screenings, kinetic immunopeptidome studies scare samples clinical contexts. To address this challenge, we developed Mild Acid Elution a Tip (MAETi), antibody-free approach low input MHC-1 profiling. Using optimized β-alanine MAE-buffer MAETi reduces background interferences, enhances peptide coverage, boosts reproducibility. Comparing bulk β-alanine-based MAE with immunoprecipitation (IP), achieves similar or complementary depth. two protocol layouts further profiled initial inputs from 25,000 1 Million cells HLA-tailored DDA- DIA-PASEF schemes yielding on average over 1,000 3,000 predicted binders, respectively (DIA). This renders facile, fast scalable method enabling robust MS-based minimal inputs. 2 Main messages / Highlights simplified workflow MHC1-ligandomics profiling sub-million cell down We present minimal, termed (MAETi) ligandome analysis using 100,000,000 per as Replacing citric acid elution buffer reduced unspecific contaminants, resulted cleaner LC-MS chromatograms boosted 8-13mer identifications 50% MAEti samples. Bulk provides coverage compared

Language: Английский

Citations

0

Recent advances in immunopeptidomic-based tumor neoantigen discovery DOI
Wei Meng, Robert D. Schreiber, Cheryl F. Lichti

et al.

Advances in immunology, Journal Year: 2023, Volume and Issue: unknown, P. 1 - 36

Published: Jan. 1, 2023

Language: Английский

Citations

0